TIGIT and Miyoshi myopathy: Our hypothesis was indirectly supported by Guillerey et al. (9) results that T cell immunoglobulin and ITIM domains (TIGIT), an immune checkpoint receptor known to negatively regulate T cell function, can be blocked by monoclonal antibodies, which increases the effecter function of MM patient CD8 + T cells and suppresses development in mice.